On Monday, Shares of JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO), lost -1.01% to $8.32.
JA Solar Holdings Co., declared the appointment of Robert Petrina as JA Solar’s Managing Director & President, North America, effective right away. Mr. Petrina will oversee the Company’s business operations in North America, drive customer growth across the utility, commercial and residential segments, and establish JA Solar as a leading partner in the market.
Robert brings more than 16 years of international business development experience in the solar industry to JA Solar. Most recently, he served as Managing Director of Yingli Green Energy Americas, overseeing sales and operations in North and South America.
Preceding to joining Yingli, Robert led global silicon procurement for General Electric’s Solar Technologies business unit. He also worked at AstroPower, Inc., spearheading the company’s silicon sourcing in Asia, Europe and North America. Mr. Petrina also served at Chori America, Inc. where he managed chemical product sales in Latin America.
JA Solar Holdings Co., Ltd., together with its auxiliaries, designs, develops, manufactures, and sells photovoltaic solar cells and solar power products based on crystalline silicon technologies. The company’s principal products comprise monocrystalline and multicrystalline solar cells and modules.
Shares of Heron Therapeutics Inc (NASDAQ:HRTX), inclined 10.03% to $28.30, during its last trading session.
Heron Therapeutics, declared the appointment of Neil J. Clendeninn, M.D., Ph.D. as Senior Vice President and Chief Medical Officer. Dr. Clendeninn joins the Company recently and will report to Barry D. Quart, Pharm.D., Chief Executive Officer of Heron.
“Neil has been instrumental as an advisor to the Company, specifically in his guidance during our recently accomplished MAGIC study for SUSTOL® (granisetron) Injection, extended release, and we are delighted that he will be joining us as a permanent member of our team,” commented Barry D. Quart, Pharm.D., Chief Executive Officer of Heron. “Neil brings over 30 years of experience in drug development and clinical practice to his role at Heron, and we look forward to his leadership in all areas of our business as we move forward in our aims of developing best-in-class medicines with the potential to improve the lives of patients suffering from cancer or pain.”
Since 2001, Dr. Clendeninn has been the president of CANAID, Inc. his own consultancy firm, and preceding to joining Heron, he was an advisor to the Company in that capacity. Additionally, Dr. Clendeninn is presently a practicing physician and serves as Program Director for Palliative Medicine Partners: Complex Illness Coordination, a program of Kauai Hospice in Kauai, Hawaii. From 1993 until 2001, Dr. Clendeninn served as Senior Vice President and Head of Clinical Affairs at Agouron Inc. Preceding to this, startning in 1985, he was Director of the Clinical Oncology Department at Burroughs-Welcome Company. Simultaneous to these roles, Dr. Clendeninn served as a practicing physician and held academic faculty roles at various institutions, among them, the University of North Carolina at Chapel Hill and the National Cancer Institute at the National Institutes of Health in Rockville, MD. In addition, Dr. Clendeninn presently sits on several Boards, counting the Board of Directors at OncoGenex Pharmaceuticals in Bothell, WA, and is a Scientific Medical Advisor at the Cancer Prevention & Research Initiative of Texas. Formerly, he served on the Board of Scientific Advisors at the National Cancer Institute of the National Institutes of Health, from 2001 through 2005. He received an M.D. and Ph.D. degree in microbiology and pharmacology from New York University in New York, NY.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company’s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials.
Finally, FMC Corp (NYSE:FMC), ended its last trade with -2.55% loss, and closed at $37.50.
FMC Corporation, declared that, due to the recent rapid devaluation of the Brazilian real, the company is reducing third-quarter and full-year outlook for its Agricultural Solutions segment. The company anticipates third-quarter segment earnings of $59 million and fourth-quarter segment earnings to be in the range of $110 to $130 million. Assuming an adjusted tax rate of 27 percent, adjusted earnings are predictable to be $0.38 per share for the third quarter and in the range of $2.35 to $2.45 per share for the full year.
A rapid devaluation of the Brazilian real, which depreciated over 50 percent as compared to the U.S. dollar in the past 12 months, and over 25 percent as compared to the U.S. dollar during the third quarter alone, has created note worthy headwinds that will continue to impact Agricultural Solutions segment earnings in the second half of 2015. Customer-held inventory levels remain elevated, limiting FMC’s ability to improvement prices quickly enough to fully offset the impact of these currency movements. During the third quarter, FMC recovered about 40 percent of the foreign exchange impact through price improvements. The company estimates that the devaluation of the Brazilian real in the second half of 2015 will reduce segment earnings by between $200 million and $240 million, which will be partially offset by price improvements of $90 million to $110 million.
FMC Corporation, a diversified chemical company, provides solutions, applications, and products for the agricultural, consumer, and industrial markets in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.